Tumor Testing Laboratories in ComboMATCH
For interested patients, molecular eligibility for the treatment trials will be determined using archival tumor tissue specimens analyzed by genetic testing laboratories designated by the National Cancer Institute (NCI) to participate in ComboMATCH (see below). Physicians routinely order these tests to guide clinical care for their patients. Only tumor assay results will be accepted for ComboMATCH. Clinical reports using ctDNA/ liquid biopsy assay results cannot be accepted at this time.
ComboMATCH-designated labs will inform oncologists at participating trial sites when patients' tumor test results show abnormalities being targeted by the drug combinations in the study. During the initial registration step, a patient's oncologist will review the test results, along with other clinical information, to determine if they are eligible for one of the treatment trials.
Nearly 40 commercial and academic labs are participating in ComboMATCH, as shown below and on this Downloadable Spreadsheet.
Commercial Designated Laboratories
Click on the lab name below to access the company website. Patients and physicians may send emails directly to commercial labs to request a review of a tumor test or seek general information. There is no need to contact the NCI or the ECOG-ACRIN Cancer Research Group.
Academic Designated Laboratories
In general, these labs, which are located in universities and at the NCI, identify potential trial candidates from their patient populations.
About NCI Designation
All ComboMATCH-designated laboratories are accredited by CLIA (Clinical Laboratory Improvement Amendments), a federal regulatory program. The NCI previously validated these laboratories to perform high-quality next-generation sequencing (NGS) assays for ComboMATCH after the labs responded to solicitations in the Federal Register. The process is now closed.
About FDA Approval
Eligibility for a ComboMATCH trial may have been determined in part based on a laboratory-developed test that has not been reviewed or approved by the FDA.
Questions?
- Patients interested in learning more about ComboMATCH should start by speaking with their doctor or healthcare team
- Reach out to the Contact Center at the National Cancer Institute, where trained specialists answer cancer-related questions in English and Spanish
- Study personnel with questions may send an email to the ComboMATCH Help Desk
Footnotes:
1 These laboratories can only provide patient referrals for treatment trials that include Insertion-Deletion Mutations (Indels) and Single Nucleotide Variant (SNV) inclusions/exclusions. Referrals for Copy Number Variants (CNVs) will not be accepted at this time.
4 These labloratories can only provide patient referrals for treatment trials that include Copy Number Variants (CNVs) and Single Nucleotide Variant (SNV) inclusions/exclusions. Referrals for Insertion-Deletion Mutations (Indels) will not be accepted at this time.
5 Only assay results from the FoundationOne®CDx assay will be accepted for ComboMATCH. Clinical reports using the FoundationOne®Liquid CDx assay results cannot be accepted.
6 Foundation Medicine may require up to 7 days after patient registration to confirm patient variant information.
7 Results from Myriad's PreciseTM Tumor assay (formerly Intermountain Precision Genomics' TheraMap Solid Tumor assay) will be accepted for ComboMATCH.
8 Due to technical limitations of the Trial Boost product, Foundation Medicine clinical lab reports dated before August 20th, 2019 cannot be used to register patients to ComboMATCH. Foundation Medicine reports must have a report identifier in the format of ORD-XXXXXXX-XX.
